HC-7366
Clear Cell Renal Cell Carcinoma (ccRCC)
Key Facts
About HiberCell
HiberCell is advancing a novel oncology platform focused on the Integrated Stress Response (ISR), a critical pathway cancer cells use to survive treatment and drive relapse. The company has three clinical-stage assets: HC-7366 and HC-5404, which target key ISR kinases, and odetiglucan, an immune modulator. With strategic collaborations and a leadership team of seasoned biotech executives, HiberCell is positioning itself to address significant unmet needs in resistant and metastatic cancers.
View full company profileAbout HiberCell
HiberCell is advancing a novel oncology platform focused on the Integrated Stress Response (ISR), a critical pathway cancer cells use to survive treatment and drive relapse. The company has three clinical-stage assets: HC-7366 and HC-5404, which target key ISR kinases, and odetiglucan, an immune modulator. With strategic collaborations and a leadership team of seasoned biotech executives, HiberCell is positioning itself to address significant unmet needs in resistant and metastatic cancers.
View full company profileTherapeutic Areas
Other Clear Cell Renal Cell Carcinoma (ccRCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |